Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease
Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease
Active, not recruiting · NCT04198922 · Registry updated 2025-11-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, neoplasm | Active, not recruiting | Phase 2 | 2025-11-05 | NCT04198922 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Fred Hutchinson Cancer Center | 123 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | United States | 140 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| Roswell Park Comprehensive Cancer Center | Buffalo | United States | 32 |
| The Ohio State University Wexner Medical Center | Columbus | United States | 102 |
| The University of Texas MD Anderson Cancer Center | Houston | United States | 207 |
| Vanderbilt University Medical Center | Nashville | United States | 71 |